Thetford Mines, Quebec – TheNewswire - June 12, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in healthcare and medical technology innovation, is proud to announce the launch of Medherize, its revolutionary new platform dedicated to the clinical management of patients requiring specialized medications. This pioneering project particularly focuses on CDK 4/6 inhibitors used in the treatment of breast cancer, with the objective of ensuring optimal and personalized patient follow-up.

Medherize marks the first collaboration among specialist doctors, pharmacists and patients to offer integrated and coordinated care. KDA’s new clinical management solution is designed to address the complex challenges associated with the administration of CDK 4/6 inhibitors, essential medications in the treatment of certain types of breast cancer. This innovative technology offers an integrated platform enabling healthcare professionals to accurately monitor patient treatments, track side effects and adjust doses in real-time while ensuring seamless communication between patients and care providers.

 

Key Features of Medherize:

• Personalized Patient Follow-Up: An intuitive user interface allowing doctors to personalize and track treatment plans for each patient, ensuring better adherence to prescribed therapies. 

• Real-Time Monitoring: Integration of monitoring devices that collect real-time data on patients’ health status, enabling rapid intervention when needed. 

• Side Effect Management: A proactive notification system to monitor and manage potential side effects of CDK 4/6 inhibitors. 

• Optimized Communication: A secure communication platform facilitating exchanges between patients, doctors and pharmacists, thereby enhancing care coordination. 

• Analysis and Reporting: Advanced analytical tools to generate detailed reports on treatment effectiveness, supporting evidence-based clinical decision-making. 

 

“We are thrilled to launch Medherize, a new technology that represents a significant step toward better healthcare management for breast cancer patients. Our solution is designed to support healthcare professionals in their mission to provide optimized and personalized treatments, while improving patients’ quality of life,” said Marc Lemieux, Chief Executive Officer of KDA.

This pilot project, the first of its kind, will be deployed in the Corporation’s partner clinics and hospitals in the coming months, with ambitions to expand internationally. KDA remains committed to investing in  innovation  and closely  collaborating  with  healthcare  professionals  to continue  developing  cutting-

edge solutions that meet the evolving needs of the healthcare sector. Artificial intelligence and new technologies could reduce healthcare spending by $200 to $360 billion.1

 

ABOUT KDA GROUP

KDA Group is a leader in technological innovations and specialized software solutions (SAAS – Software as a Service) for the healthcare professionals’ market. KDA is a corporation that offers quality products and has a respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare’s digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at www.kdagroup.com and on SEDAR+ at www.sedarplus.ca.

 

- 30 -

 

REFERENCE

1- David M. Cutler et al., The potential impact of artificial intelligence on healthcare spending, National Bureau of Economic Research working paper, number 30857, January 2023.

 

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

 

This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

 

INFORMATION

Marc Lemieux, Chief Executive Officer

514 622-7370

info@groupekda.ca